Vivus ( VVUS +1.9% ) continues to trade higher this week on hopes the company may partner with Big Pharma to expand access to the obesity drug Qsymia ( I , II ). Nevertheless, some, like Lazard's Joshua Schimmer, say the reality is that demand for the drug has so far proven tepid and VVUS "needs to ... Vivus ( VVUS ) rises 2.6% premarket after sending a "business update" letter to shareholders outlining its progress on expanding access to its obesity drug Qsymia. The company reiterates some of the points made on the CC saying it is in discussions with Big Pharma regarding increasing the product's ... Vivus ( VVUS -3.3% ) slips today after pricing its $220M private placement of convertible senior unsecured notes due May 1, 2020. The notes will bear interest at a fixed annual rate of 4.50%, payable semiannually in arrears on May 1 and November 1 of each year, beginning on November 1, 2013. The ... Vivus ( VVUS +2.2% ) says that Qsymia has been added to Medco's national formulary in a tier-3 position with a prior authorization. According to Leerink Swann, the deal essentially converts Qsymia reimbursement from the non-covered to the covered position, and is potentially more important than the ... Vivus ( VVUS -3.3% ) is apparently mortgaging future sales of its new weight-loss drug Qsymia in exchange for up to $110M in new synthetic financing with an investment fund managed by Pharmakon Advisors. Under the terms, VVUS will make an initial draw of $50M, with the option for an additional $60M ... Vivus ( VVUS ) rises 5.4% premarket after saying in an 8K that sales of Qsymia rose 29% in March. The company now reports Qsymia shipments by the calendar month: January 16,733; February 18,417; March 23,812. Post your comment! Vivus ( VVUS +5% ) spikes as the FDA approves its amendment and modification to the Risk Evaluation and Mitigation Strategy for Qsymia. The amendment, which was submitted last October, allows Qsymia to be dispensed through certified retail pharmacies in addition to the existing network of certified ... Shares of Vivus ( VVUS +3.5% ) finish solidly in the green today as investors continue to expect Risk Evaluation and Mitigations Strategy modification for Qsymia. Cowen specutlates that many shorts are covering positions ahead of the decision. As of the end of March , over 26M shares, or 26% of the ... Shares of Vivus ( VVUS ) are active in the post session on speculation that Johnson & Johnson ( JNJ ) and AstraZeneca ( AZN ) are considering a takeover of the drug developer due to the company's obesity drug Qsymia. Pfizer ( PFE ) may also take an interest should VVUS come under takeover attack, ... Vivus ( VVUS ) -4.7% to $13.65 after receiving a downgrade from Hold to Sell from Brean Capital, which suggests a downside of over 50% on yesterday's close of $14.32 by setting a price target of $7. Brean Capital points out that just one in five patients are covered by insurance for Vivus' Qsymia ...